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Assessment of liver and kidney  functions in patients receiving 
antipsychotic and antiepileptic  drugs in Gaza. 
Abstract 
Background: many drugs affect liver and kidney functions, among these, drugs used 
to treat psychotic patients such as chlorpromazine (CPZ) which is used to treat 
schizophrenia and  Trihexyphenidyl- hydrochloride ( T.H.P) which is used to treat side 
effect of antipsychotic medication, another  drug which is  used to treat epilepsy is 
valproic  acid (VPA)  which may affect the liver and kidney functions. 
Objective: This study aims at assessing liver and kidney functions in patients 
receiving antipsychotic and antiepileptic  drugs for more than one year . 
Materials and methods: The present study is a case control study  comprised of  
220 subjects including 110 psychiatric and epileptic  patients from Mental health clinics 
in Gaza and 110 healthy people as  a control group.  Experimental work was done by 
using five ml blood were collected from each subject into vacutainer  plain tubes. Serum 
Gamma glutamyltransferase (GGT), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), Serum urea, creatinine, uric acid, alkaline phosphatase (ALP), 
serum total and direct bilirubin ( TB, DB) were assayed biochemically using biosystem 
autoanalyze. Spss was used to analyze obtained data.                          
Results: The liver and kidney function  tests among epileptic patients receiving 
Valproic Acid (VPA) showed high statistically  significant differences  between cases  
and control groups  with respect to AST test. While liver and kidney function tests in 
psychiatric  patients suffered from schizophrenia  receiving chlorpromazine (CPZ) with  
Trihexyphenidyl hydrochloride (T.H.P) showed, significant differences between  cases 
and control group in relation to AST, ALP, GGT, DB , creatinine and uric acid tests 





                                                                                    .                              
 تقييم وظائف الكبد والكلى لدى المرضى النفسيين ومرضى الصرع في غزة
 مستخلص الدراسة 
األدوية  التي تستخدم لعالج   ، منهاتؤثر على وظائف الكبد والكلى التي  العديد من األدويةهناك  المقدمة:
فينديل هيدروكلوريد و الذي  وترايهكس كلوربرومازين الذي  يستخدم لعالج انفصام الشخصية، المرضى النفسيين مثل
 يستخدم لعالج الصرع.الذي  فالبرويك حامض ال دواء و، يستخدم لعالج اآلثار الجانبية لألدوية النفسية
 ألكثر من سنة. يتعاطون االدويةتقييم وظائف الكبد والكلى لدى المرضى النفسيين ومرضى الصرع الذين   الهدف:
مصابون بالصرع والمرض النفسي  امريض   112من بينهم  صا  شخ 222من  هذه الدراسة مكونة الطرق واألدوات:
وقد تمت الفحوصات كعينة ضابطة.  ا  سليم صا  شخ 112و الصحة النفسية في غزة، من عيادات تم تجميعهم
جراء عليها فحوصات الكبد والكلى 5ب سحبلهذه الدراسة    المخبرية بواسطة تقنية التحليل  مل دم من كل مريض وا 
 التى حصلنا عليها. تالبيانافى تحليل  Spssوتم استخدام برنامج  ، اللىا
الفالبرويك ارتفاع في فحص حامض  أظهرت فحوصات الكبد والكلى لدى مرضى الصرع الذين يتناولون النتائج :
بينما ال يوجد أي  داللة إحصائية، ذوعند مقارنته بنتائج العينة الضابطة وهذا االرتفاع ، مينوترانسفيريزأسبرتيت األ
 ،واليوريا ،مينوترانسفيريزألنين واأل ،الجاما جلوتميل ترانسفيرز دالالت  إحصائية في الفحوصات األخرى مثل
 والبليروبين الكلى والمباشر. ،وااللكالين فوسفتيز ،اليوريك حامض  و ،والكرياتنين
من مرض انفصام الشخصية الذين يتناولون أظهرت فحوصات الكبد والكلى لدى المرضى النفسيين الذين يعانون و 
 ،ترايهكسفينديل هيدروكلوريد انه يوجد ارتفاعات في فحوصات  الجاما جلوتميل ترانسفيرز عالج الكلوربرومازين مع
عند مقارنتها  ،والبليروبين المباشر ،لكالين فوسفتيزواأل ، اليوريكحامض  و ،والكرياتنين ،مينوتراتسفيريزأسبرتيت واأل
والبيليروبين  ،واليوريا ،مينو ترانسفيرزألنين فحوصات األ بينما ال توجد أي ارتفاعات في ائج العينة الضابطة،بنت
 .يالكل
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Psychosis: from the Greek "psyche", for mind or soul, and "-osis ", for abnormal 
condition literally means abnormal condition of the mind, and is a generic psychiatric 
term for a mental state often described as involving a "loss of contact with reality" (1) . 
People suffering from psychosis are said to be psychotic. People with psychosis may 
have one or more of the following: hallucinations, delusions, or thought disorder. The 
exact cause of psychotic disorders is unknown. Psychosis may appear as a symptom of a 
number of mental disorders including mood and personality disorders, schizophrenia, 
and  delusional disorder. Schizophrenia is a particular type of psychosis that is, a mental 
disorder caused by some inherent dysfunction of the brain. it is characterized by 
delusions, hallucination (often in the form of voices), and thinking or speech 
disturbances (2). This mental disorder is a common affliction, occurring  among about 
one percent of the population (3). Many antipsychotic drugs are available for the 
treatment of schizophrenia. These drugs such as: Chlorpromazine, Haloperidol, 
Risperidone, exert blocking effects on a wide range of receptors including dopamine 
and adrenoceptor, muscarinic, H1 histaminic, and serotonin (5-HT2). Dopamine 
receptor effects quickly became the major focus of interest. Dopamine receptors control 
neural signaling that modulates many important behaviors, such as spatial working 
memory (4).The epilepsies are one of the most common serious  brain disorders, which  
can occur at all ages, and have many possible presentations and causes. 
 Although incidence in childhood has fallen over the past three decades in developed 
countries (5). It rounds 50 cases per 100 000 of the population. The aim of drug therapy 
is to prevent, cure or control various disease states. To achieve this, adequate drug doses 
must be delivered to the target tissues. 
After the absorption of the  drug, it is metabolized in the liver, The liver is the 
largest organ of  the human body, weighs approximately 1500 g, and is located in the 
upper right corner of the abdomen. The liver metabolizes virtually every drug or toxin 
introduced in the body(6). Most drugs are lipophilic (fat soluble), enabling easy 
absorption across cell membranes. In the body, they are rendered hydrophilic (water 
soluble) by biochemical processes in the hepatocytes to enable inactivation and easy 
excretion. Metabolism  of drugs occurs in 2 phases. In the phase 1 reaction, the drug is 
made polar by oxidation or hydroxylation. 
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Cytochrome P450s play a central role in the metabolism and disposition of an 
extremely wide range of drugs and chemical carcinogens (7). Most of these intermediate 
products are transient and highly reactive. These reactions may result in the formation 
of metabolites that are far more toxic than the parent substrate and may result in liver 
injury.  
Phase 2 reactions may occur within or outside the liver. They involve 
conjugation with a moiety (i.e., acetate, amino acid, sulfate, glutathione, glucuronic 
acid) that further increases solubility. Subsequently, drugs with high molecular weight 
may be excreted in bile, while the kidneys excrete the smaller molecules (8). Removal 
of a drug from the body may occur via a number of routes, the most important being 
through the kidney into the urine. other routes include the bile, intestine, lung, or milk in 
nursing mothers. kidney is Small, dark red organs with a kidney bean shape which lies 
against the dorsal body wall in a retroperitoneal position in the superior lumbar region 
where they receive some protection from the lower part of the rib cage. the function of 
the kidney is the  clearance  of  nitrogenous wastes while regulating water, electrolytes 
and acid base- balance of the blood . 
1.2 General objective 
This study aims to assess liver and kidney functions in patients receiving 
antipsychotic and antiepileptic  drugs for more than one year in Gaza .   
1.3 Specific objectives  
To examine changes in the levels of: 
1. Serum alanine aminotransferase (ALT). 
2.  Aspartate aminotransferase (AST). 
3.  Alkaline phosphatase (ALP). 
4.  Total bilirubin (TB), and Direct bilirubin (DB). 
5. Gamma glutamyl transferase (GGT). 
6. Urea, creatinine, and uric acid in patients receiving antipsychotic and 
antiepileptic drugs . 
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1.4 Significance  
Although antipsychotic drugs are used in Gaza for long time, their toxic effects 
have not been investigated. It is well known that many of these drugs affect liver and or 
kidney functions. For this reason and due to increased number of patients receiving 
antipsychotic drugs in our area, this study has been designed to study the effects of 
these drugs on liver and kidney function of those patients and to alert physicians about 
the harmful consequences of these drugs so they could initiate early action to prevent or 
delay such consequences. According to the knowledge of researcher, this study is the 

































LITERATURE  REVIEW 
The aim of drug therapy is to prevent, cure or control various disease states. To 
achieve this goal, adequate drug doses must be delivered to the target tissues .  
2. 1Transfer of drugs from GIT across cell membranes 
In general, drugs may cross cell membranes by (9) 
_ Passive diffusion 
_ Carrier transport 
2.2 Bioavailability 
Bioavailability is used to describe the fraction of an administered dose of 
unchanged drug that reaches the systemic circulation, one of the principal 
pharmacokinetic properties of drugs. By definition, when a medication is administered 
intravenously, its bioavailability is 100%. However, when a medication is administered 
via other routes (such as orally), its bioavailability decreases (due to incomplete 
absorption and first-pass metabolism) or may vary from patient to patient due to inter-
individual variation (10). 
2.2.1 Factors influencing bioavailability 
Whether a drug is taken with or without food will also affect absorption, other drugs 
taken concurrently may alter absorption, first-pass metabolism and  intestinal motility 
alters the dissolution of the drug and may affect the degree of chemical degradation of 
the drug by intestinal microflora. Disease states affecting liver metabolism or 
gastrointestinal function will also have an effect (11).  Other factors may include:   
 The drug formulation (immediate release, or delayed release).  
 Enzyme induction/inhibition by other drugs/foods:  
o Enzyme induction (increase rate of metabolism). e.g. Phenytoin 
(antiepileptic) induces CYP1A2, CYP2C9, CYP2C19 and CYP3A4 
o Enzyme inhibition (decrease rate of metabolism). e.g. grapefruit juice 
inhibits CYP3A . 
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2.3 Drug distribution 
After administration and absorption, drugs are initially present in plasma and 
may be partly bound to plasma proteins. They may subsequently gain access to 
interstitial fluid and intracellular water, depending on their physicochemical properties 
(in particular, their lipid solubility and ionic dissociation), blood flow, capillary 
permeability and the degree of binding of  the drug to plasma and tissue proteins, 
consequently  they may be rapidly distributed in other tissues and organs. When 
distribution is complete, their concentration in plasma water and extracellular fluid is 
approximately equal (12). Some drugs are extensively protein-bound and are 
predominantly present in plasma. Similarly, ionized compounds cannot readily 
penetrate most cell membranes and in contrast  lipid-soluble drugs with a relatively low 
molecular weight are widely distributed in tissues. For instance, ethyl alcohol, urea and 
some sulphonamides are evenly distributed throughout body water.  
2.4 Drug metabolism 
Most drugs are eliminated by drug metabolism, which mainly occurs in the liver. 
Nevertheless, certain drugs are partly or completely broken down by other tissues. Such 
as metabolized by the gut (e.g. morphine, chlorpromazine), the kidney  (e.g. midazolam, 
dopamine) or the lung (e.g. angiotensin, prilocaine). Nevertheless, the liver is mainly 
responsible for the breakdown of drugs. Hepatic metabolism decreases the 
concentration of the active drug in plasma, and thus promotes its removal from the site 
of action. This mainly involves the enzymatic conversion of lipid-soluble non polar 
drugs into water-soluble polar compounds (13) which can be filtered by the renal 
glomerulus or secreted into urine or bile. 
 Metabolism usually reduces the biological activity of drugs, and most 
metabolites have less inherent activity than their parent compounds. In addition, their 
ability to penetrate to receptor sites is limited because of their poor lipid solubility. 
Although almost all tissues in the body have some ability to metabolize chemicals, 
smooth endoplasmic reticulum in liver is the principal "metabolic clearing house" for 
both endogenous chemicals (e.g., cholesterol, steroid hormones, fatty acid and proteins), 
and exogenous substances (e.g. drugs) (14). 
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 Drug metabolism is usually divided into two phases: phase 1 and phase 2. Phase 
1 reaction is thought to prepare a drug for phase 2. However many compounds can be 
metabolized by phase 2 directly. Phase 1 reactions involves oxidation, reduction, 
hydrolysis, hydration and many other rare chemical reactions (15). These processes tend 
to increase water solubility of the drug and can generate metabolites which are more 
chemically active and potentially toxic. Most of phase 2 reactions take place in cytosol 
and involve conjugation with endogenous compounds via transferase enzymes. 
Chemically active phase 1 products are rendered relatively inert and suitable for 
elimination by this step. A group of enzymes located in the endoplasmic reticulum, 
known as cytochrome P-450, is the most important family of metabolizing enzymes in 
the liver ( 16). 
2.5 The Liver 
The liver is the largest organ of the human body, weighs approximately 1500 g 
(17), and is located in the upper right corner of the abdomen. The organ is closely 
associated with the small  intestine, processing the nutrient-enriched venous blood that 
leaves the digestive tract. The liver performs  over 500 metabolic functions, resulting in 
synthesis of products that are released into the blood stream (e.g. glucose derived from 
glycogenolysis, plasma proteins, clotting factors and urea), or that are excreted to the  
intestinal tract (bile). Also, several products are stored in liver parenchyma (e.g. 
glycogen, fat and fat  soluble vitamins) (18). Almost all blood that enters the liver via 
the portal tract  originates from the gastrointestinal tract as well as from the spleen, 
pancreas and gallbladder. A second  blood supply to the liver comes from the hepatic 
artery, branching directly from the celiac trunc and  descending aorta. The portal vein 
supplies venous blood under low pressure conditions to the liver, while  the hepatic 
artery supplies high-pressured arterial blood. Since the capillary bed of the 
gastrointestinal tract already extracts most O2, portal venous blood has a low O2 
content. Blood from the hepatic artery on the  other hand, originates directly from the 
aorta and is, therefore, saturated with O2 (19). The liver alters exogenous and 
endogenous chemicals , foreign molecules, and hormones to  make them less toxic or 




  The kidney performs important physiological functions including maintenance 
of  water and electrolyte balance, synthesis, metabolism and secretion of hormones and 
excretion of waste products from metabolism. In addition, the kidneys play a major role 
in excretion of drugs, hormones and xenobiotics (20) Although the kidney will 
generally metabolize endogenous or exogenous chemicals to compounds with reduced 
biological activity, there are several instances in which metabolism will produce a toxic 
intermediate that may result in mutagenesis or cell necrosis (21). 
 
2.7 Cytochrome P450 
Cytochrome P450 (abbreviated CYP, P450, infrequently CYP450) is a very 
large and diverse superfamily of  hemoproteins ( 22). Usually they form part of multi-
component electron transfer chains, called P450-containing systems.  The most 
common reaction catalysed by cytochrome P450 is a monooxygenase reaction, e.g. 
insertion of one atom of oxygen into an organic substrate (RH) while the other oxygen 
atom is reduced to water: 




 → ROH + H2O 
The name cytochrome P450 is derived from the fact that these are colored ('chrome') 
cellular ('cyto') proteins, with a "pigment at 450 nm", so named for the characteristic 
peak formed by absorbance of light at wavelengths near 450 nm when the heme iron is 
reduced (often with sodium dithionite) and complexed to carbon monoxide ( 23). 
2.7.1 CYP 450s in humans 
Human CYPs are primarily membrane-associated proteins, located either in the 
inner membrane of mitochondria or in the endoplasmic reticulum of cells. CYPs 
metabolize thousands of endogenous and exogenous compounds. CYPs are responsible 
for the biosynthesis of physiologically important compounds such as steroids, fatty 
acids, fat-soluble vitamins and bile acids, the conversion of alkanes and aromatic 
compounds as well as the degradation of herbicides and insecticides (24). Most  CYPs 
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can metabolize multiple substrates, and many can catalyze multiple reactions, which 
accounts for their central importance in metabolizing the extremely large number of 
endogenous and exogenous molecules. In the liver, these substrates include drugs and 
toxic compounds as well as metabolic products such as bilirubin. Cytochrome P450 
enzymes are present in most other tissues of the  body, and play important roles in 
hormone synthesis and breakdown (including estrogen and testosterone synthesis and 
metabolism), cholesterol synthesis, and vitamin D metabolism. The Human Genome 
Project has identified 57 human genes coding for the various cytochrome P450 enzymes 
( 25). 
2.7.2 Mechanism of action  
 The active site of cytochrome P450 contains a heme iron center. The iron is 
tethered to the P450 protein via a thiolate ligand derived from a cysteine residue. 
Because of the vast variety of reactions catalyzed by  CYPs, the activities and properties 
of the many CYPs differ in many aspects. In general, the P450 catalytic cycle proceeds 
as follows: 
1: The substrate binds to the active site of the enzyme, in close proximity to the heme 
group, on the side opposite to the peptide chain. The bound substrate induces a change 
in the conformation of the active site  often displacing a water molecule from the distal 
axial coordination position of the heme iron
 
(26).  
2: The change in the electronic state of the active site favors the transfer of an electron 
from NAD(P)H via cytochrome P450 reductase or another associated reductase.
  
This 
takes place by way of the electron transfer chain, reducing the ferric heme iron to the 
ferrous state (27). 
3: Molecular oxygen binds covalently to the distal axial coordination position of the 
heme iron. The cysteine ligand is a better electron donor than histidine, with the oxygen 
consequently being activated to a greater extent than in other heme proteins. However, 
this sometimes allows the bond to dissociate, the so-called "decoupling reaction", 
releasing a reactive superoxide radical, interrupting the catalytic cycle. 
 4: A second electron is transferred via the electron-transport system, either from 
cytochrome P450 reductase, ferredoxins, or cytochrome b5, reducing the dioxygen 
adduct to a negatively charged peroxo group. This is a short-lived intermediate state. 
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5: The peroxo group formed in step 4 is rapidly protonated twice by local transfer from 
water or from surrounding amino-acid side chains, releasing one water molecule, and 
forming a highly reactive iron(V)-oxo species. as shown in fig.1 
 6: Depending on the substrate and enzyme involved, P450 enzymes can catalyse any of 
a wide variety of reactions. A hypothetical hydroxylation is shown in fig.1                
After the product has been released from the active site, the enzyme returns to its 
original state, with a water molecule returning to occupy the distal coordination position 




Figure1: mechanism of action of  CYP 450.
(29) 
2.7. 3 Phase 2 reactions 
Phase 2 reactions (synthetic reactions) involve the conjugation of other chemical 
groups with the oxidized, reduced or hydrolysed products of phase 1 reactions. Some 
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relatively polar drugs may only be metabolized by phase 2 reactions. The metabolic 
changes that occur during phase2 reactions usually involve the addition of glucuronide,  
sulphate, acetate, glycine or methyl groups to the products of phase 1 reactions. The 
most important of these reactions is glucuronide conjugation. 
2.7. 3.1Glucuronide conjugation 
The conjugation of drugs to glucuronides is mainly dependent on enzyme 
systems in the hepatic endoplasmic reticulum. The microsomal enzyme glucuronyl 
transferase catalyses the transfer of glucuronide residues from UDP glucuronide to 
unconjugated compounds (21). This process is responsible for the conjugation of 
endogenous compounds (e.g. bilirubin, thyroxine) as well as many drugs (e.g. 
morphine, steroid hormones).  
2.8 Mechanism of liver damage 
The pathophysiologic mechanisms of hepatotoxicity are still being explored and 
include both hepatocellular and extracellular mechanisms. The following are some of 
the mechanisms that have been described (30): 
1. Disruption of the hepatocyte: Covalent binding of the drug to intracellular 
proteins can cause a decrease in ATP levels, leading to actin disruption. 
Disassembly of actin fibrils at the surface of the hepatocyte causes blebs and 
rupture of the membrane. 
2. Cytolytic T-cell activation: Covalent binding of a drug to the P-450 enzyme acts 
as an immunogen, activating T cells and cytokines and stimulating a 
multifaceted immune response.  
3. Toxic metabolites may alter plasma membrane, mitochondria, intracellular ion 
homeostasis, or degradative enzyme activity (31). 
4. Many chemicals damage mitochondria. Its dysfunction releases excessive 
amount of oxidants which, in turn, injure hepatic cells ( 32). 
5. Bile duct injury: Toxic metabolites excreted in bile may cause injury to the 
bile duct epithelium. Injury to hepatocyte and bile duct cells lead to 
accumulation of bile acid inside liver. This promotes further liver damage (33) 
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The classic view on the pathogenesis of drug-induced liver injury is that the so-
called parent compounds are   made hepatotoxic by metabolism (formation of neo-
substances that react abnormally), mainly by cytochromes P-450 (CYP)(34).    
Activation of some enzymes in the cytochrome P-450 system such as CYP2E1 also 
lead to oxidative stress (35). Chemicals produce a wide variety of clinical and 
pathological hepatic injury. Biochemical markers (i.e. alanine transferase, aspartate 
transferase, glytamile transferase, alkaline phosphatase and bilirubin) are often used 
to assess liver damage ( 36).                                        
 
2.9 Neurotransmitters 
Neurotransmitters, are endogenous chemicals that transmit signals from a 
neuron to a target cell across a synapse, have long been thought to be involved in the 
development of schizophrenia. 
2.9.1 Dopamine  
Dopamine is a catecholamine neurotransmitter found in neurons of both the 
central and peripheral nervous systems (37). It is stored in vesicles in axon terminals and 
released when the neuron is depolarized (38). Dopamine interacts with specific 
membrane receptors to produce its effects. In the brain, this phenethylamine functions as 
a neurotransmitter, activating the five types of dopamine receptors—D1, D2, D3, D4, and 
D5—and their variants. Dopamine is produced in several areas of  the brain, including 
the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone 
released by the hypothalamus. Its main function as a hormone is to inhibit the release of 
prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the 
brain, including important roles in behavior and cognition, voluntary movement, 
motivation and inhibition of prolactin production (involved in lactation), sleep, mood, 
attention, and learning (39). These effects are terminated by re-uptake into the 
presynaptic neuron by a dopamine transporter, or by metabolic inactivation by 
monoamine oxidase B (MAO-B) or catechol-o-methyltransferase (COMT). Dopamine is 
widely distributed in the brain and is one of the neurotransmitters that enables 
communication in the circuits that link subcortical with cortical brain regions (40). 
Recent studies (41) have suggested that various positive symptoms of schizophrenia 
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correlate with abnormalities in presynaptic dopamine storage, release, transport, and 
reuptake in mesolimbic systems. 
2.9.2 Serotonin 
Serotonin is 5-hydoxytryptamine which is often abbreviated to 5-HT. It is made 
from the amino acid, tryptophan. Serotonin is converted to melatonin in the pineal 
gland, which lies deep at the centre of the human brain, The average adult human 
possesses only 5 to 10 mg of serotonin, 90 % of which is in the intestine (42) and the 
rest in blood platelets and the brain (43). Tryptophan, derived from food, is transported 
to the brain to make the neurotransmitter serotonin.  At the appropriate place inside a 
brain cell, two enzymes and vitamin B6 transform tryptophan to serotonin. Serotonin is 
then transferred to the sending end of the neuron, where it is used as a molecular 
messenger to carry information across the synapse to the receiving neuron. The 
serotonin molecules can then bind to receptor proteins within the postsynaptic cell, 
which causes a change in the electrical sate of the cell. This change in electrical state 
can either excite the cell, passing along the chemical message, or inhibit it.  Excess 
serotonin molecules are taken back up by the presynaptic cell and reprocessed (44). The 
serotonin synthesis equation is:  
STEP 1. Tryptophan-----> 5-Hydroxytryptophan via enzyme tryptophan hydroxylase. 
STEP 2. 5-Hydroxytryptophan (5HT)----> Serotonin via enzyme 5HT-Decarboxylase. 
The functions of serotonin are numerous and appear to involve control of appetite, 
sleep, memory and learning, temperature regulation, mood, cardiovascular function, 
muscle contraction, endocrine regulation and depression (45). Low serotonin levels are 
believed to be the cause of many cases of mild to severe depression which can lead to 
symptoms such as anxiety, fear  feelings of worthlessness, insomnia and fatigue and 
suicide.  Too little also leads to an increased appetite for carbohydrates and trouble 
sleeping, which are also associated with  depression and other emotional disorders (46) 
2.9.3 Gamma-Amino Butyric acid (GABA)  
Gamma-Amino Butyric acid  is an amino acid which acts as a neurotransmitter 
in the central nervous system. It inhibits nerve transmission in the brain (47), calming 
nervous activity. GABA is formed within GABAergic axon terminals and released into 
the synapse, where it acts at one of two types of receptors: GABAA,  which controls 
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chloride entry into the cell, and GABAB, which increases potassium conductance, 
decreases calcium entry, and inhibits the presynaptic release of other transmitters (48). 
  GABA does not penetrate the blood-brain barrier; it is synthesized in the brain. It is 
synthesized from glutamate using the enzyme L-glutamic acid decarboxylase (49) and 
pyridoxal phosphate (which is the active form of vitamin B6) as a cofactor via a 
metabolic pathway called the GABA shunt. This process converts glutamate, the 
principal excitatory neurotransmitter, into the principal inhibitory neurotransmitter 
(GABA) (50). After release from the presynaptic axon terminals, GABA is rapidly 
removed by uptake into both glia and presynaptic nerve terminals and then is 
catabolized by GABA transaminase to succinic semialdehyde.  Succinic semialdehyde 
is converted to succinic acid by succinic acid semialdehyde dehydrogenase and then 
enters the Krebs cycle . 
2.10 Psychosis Disorder 
2.10.1 Schizophrenia 
Schizophrenia is one of the terms used to describe a major psychiatric disorder 
that alters process of thinking, emotional responsiveness (51), most commonly 
manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized 
speech and thinking, and it is accompanied by significant social or occupational 
dysfunction (52). 
Typically, the problems of schizophrenia are preceded by a ‘prodromal’ period (53), this 
is often characterized by some deterioration in personal functioning. Difficulties may 
include memory and concentration problems, social withdrawal, unusual and 
uncharacteristic behaviour, bizarre ideas, poor personal hygiene, and reduced interest in 
and motivation for day-to-day activities. The prodromal period is typically followed by an 
acute phase marked by characteristic positive symptoms of hallucinations, delusions, and 
behavioural disturbances . 
2.10.1.1  Prevalence  
 
 Affecting nearly 1 % of the world's population (54). 
 Schizophrenia affects men and women equally (55). Men with an earlier age of 
onset. Behavioral deficits, and a poorer response to chemotherapy (56). 
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 Schizophrenia typically occurs in late adolescence or early adulthood( 57), at the 
very time that people are making  their way from the family into the world 
outside. Most of the time people do not get schizophrenia after age 45 (58). 
Schizophrenia is rarely diagnosed but possible before age 10 ( 59). 
 The standardized mortality ratio (SMR; ratio of observed deaths to expected         
      deaths) for all-cause mortality is 2.6 for patients with schizophrenia compared to 
     the general population (60), excess deaths mainly from suicide during the early 
     phase of the disorder and accidents . 
2.10.1.2  Symptoms of schizophrenia    
Schizophrenia is often described in terms of positive and negative symptoms (61) 
The term Positive symptoms are psychotic behaviors not seen in healthy people but are 
present in schizophrenia. These unusual experiences are most common in 
schizophrenia, but can occur in other mental disorders . They include;    
1. Delusions  
2. Hallucinations(62) 
3. Disturbances in thought and speech. 
                                                                                                                                     
2.10.1.3 Subtypes of schizophrenia  
1. Paranoid Subtype 
The defining feature of the paranoid subtype is the presence of auditory 
hallucinations or prominent delusional thoughts about persecution or conspiracy (63). 
However, people with this subtype may be more functional in their ability to work and 
engage in relationships than people with other subtypes of schizophrenia. 
2. Disorganized Subtype 
As the name implies, this subtype’s predominant feature is disorganization of the 
thought processes. As a rule, hallucinations and delusions are less pronounced, although 
there may be some evidence of these symptoms (64).  These people may have 
significant impairments in their ability to maintain the activities of daily living. Even 
the more routine tasks, such as dressing, bathing or brushing teeth,  can be impaired, 
emotional processes of the individual can be impaired as well. 
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3. Catatonic Subtype 
The predominant clinical features seen in the catatonic subtype involve disturbances 
in movement. Affected people may exhibit a dramatic reduction in activity, to the point 
that voluntary movement stops, as in catatonic stupor. Alternatively, activity can 
dramatically increase, a state known as catatonic excitement. Other disturbances of 
movement can be present with this subtype (65). 
4. Undifferentiated subtype: Psychotic symptoms are present (no single type of 
symptoms prominent than other ) but the criteria for paranoid, disorganized, or 
catatonic types have not been met. 
5. Residual subtype: Where positive symptoms are present at a low intensity only 
It is possible for schizophrenia to co-exit with other mental illnesses .  Schizophrenia 
puts individuals at especially high risk for depression and suicide attempts .when a person 
experiences both schizophrenia and a mood disorder they are diagnosed with 
Schizoaffective Disorder . 
2.10.1.4 Chlorpromazine   
While current antipsychotic drug treatments control positive symptoms in most 
patients, negative symptoms and cognitive impairments are much less improved by 
these agents (66) Antipsychotic medication can be divided into two major classes. 
Conventional antipsychotic medications, first introduced in the 1950s, are usually 
referred to as either “typical” or “first -generation” antipsychotics . 
Chlorpromazine (Thorazine), was the first antipsychotic medication, All of these 
medications reduce dopamine activity by blocking dopamine receptors, especially the D2 
subtype, and these drugs have similar efficacy for the positive symptoms of 
schizophrenia. They differ from each other, however, in side-effect profiles. Drug induced 
movement abnormalities are the main side effect associated with the typical 
antipsychotics (67). The cause of the motor side effects is not established, but is assumed 
to be due to excessive dopamine D2 receptor blockade. The motor symptoms typically 
decline following the discontinuation of medication. In the 1990’s, new antipsychotic 
medications were developed. These new medications are called second generation, or 
“atypical” antipsychotics. They differ significantly from one another in terms of the 
neurotransmitter receptors that they occupy. However, they all act as dopamine 
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antagonists to some extent, in addition to affecting other neurotransmitter systems, and 
they have a reduced risk of both the early and late emerging movement disorders (68) 
Chlorpromazine (as chlorpromazine hydrochloride, abbreviated CPZ; marketed 
in the United States as Thorazine and elsewhere as Largactil) is a typical antipsychotic  
(69). Chlorpromazine was the first drug developed with specific antipsychotic action, 
and would serve as the prototype for the phenothiazine class of drugs . Chlorpromazine 
works on a variety of receptors in the central nervous system, producing anticholinergic, 
antidopaminergic, antihistaminic, and weak antiadrenergic effects. Both the clinical 
indications and side effect profile of CPZ are determined by this broad action: its 
anticholinergic properties cause constipation, sedation, and hypotension, and help 
relieve nausea (70).                                                                        
2.10.1.4.1 Pharmacokinetics 
Chlorpromazine, and many other phenothiazine derivatives, are highly lipophilic 
molecules that readily bind with membranes and proteins. Around 95-98% of the drug 
is bound in the plasma; 85% of the drug is bound to the plasma protein albumin. It is a 
dopamine inhibitor, increases dopamine turnover in the brain, and stimulates prolactin 
release, Chlorpromazine is widely distributed in the body and crosses the blood-brain 
barrier to achieve higher concentrations in   the brain than in the plasma (71), The drug 
can also enter fetal circulation and breast milk.  Bioavailability of CPZ is Only about 
32% of the administered dose which is available to the systemic circulation in the active 
form. Over time and multiple administrations, bioavailability may drop to 20%. Peak 
concentrations are achieved in 1 to 4 hours (72). CPZ is slowly absorbed from the 
intramuscular injection site with the peak plasma concentration  occurring 6–24 hours 
after administration of the drug. The oral bioavailability is estimated to be 30–50% that 
of intramuscular doses and about 10% that of intravenous doses due to extensive first 
pass metabolism in the liver. Its elimination half-life is 16–30 hours. Chlorpromazine is 
typically degraded by the liver by the action of cytochrome-P450 family enzymes, 
usually CYP2D6 (73). Less than 1% of the unchanged drug is excreted via the kidneys 
in the urine. In which 20-70% is excreted as conjugated or unconjugated metabolites, 
whereas 5-6% is excreted in feces.  Often, due to their high lipophilic character, these 
and other metabolites may be detected in the urine up to 18 months (74). 
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2.10.1.4.2 Dosage  
Adults: Initially 25mg three times daily or 75mg at bedtime, increasing by daily 
amounts of 25mg to the effective maintenance dose. The usual maintenance dose is in 
the range of 75 to 300 mg daily, although some patients may require up to 1.0 g daily 
(75). oral dose for children aged over 5 years is usually one-third to one-half of the 
adult dose. Daily doses should not normally exceed 75 mg for children over 5 years of 
age (76 ). 
  
2.10.1.5 Trihexyphenidyl hydrochloride ( T.H.P) 
Trihexyphenidyl hydrochloride is a type of anticholinergic drug  that works by 
blocking the effects of acetylcholine neurotransmitter (77). Trihexyphenidyl is used 
alone or together with other medicines  to treat Parkinson's disease. This helps decrease 
muscle stiffness, sweating, and the production of saliva, and helps improve walking 
ability in people with Parkinson's disease, and to  treat involuntary movements due to 
the side effects of certain psychiatric drugs (antipsychotics such as chlorpromazine, 
haloperidol). These compounds have also been reported to improve negative and 
depressive symptoms of schizophrenia(78). Trihexyphenidyl is rapidly absorbed from 
the gastrointestinal tract. The onset of action is within 1 hour after oral dosing. The peak 
activity is noted after 2 to 3 hours. It is excreted in the urine, probably as unchanged 
drug (79), its brand name is Artane. 
2.10.1.5.1 Dosage 
Trihexyphenidyl is available in 2-mg and 5-mg tablets, it should be started at a 
dose of 1 to 2 mg orally two to three times daily or as needed, to a maximum daily 
dose of 15 mg per day in Parkinson's disease. In  extrapyramidal side effects : 
Usually, 5 to 15 mg daily are needed in 2 or 3 divided doses. Some patients, 




2.11 Neurological disorder 
2.11.1 Epilepsy     
Epilepsy: (The word “epilepsy”  is derived from Latin and Greek words for 
“seizure” . It's a common chronic neurological disorder characterized by seizures (81), 
the tendency to have recurrent attacks is known as epilepsy. The brain is a highly 
complex and sensitive organ. It controls and regulates all our actions, movements, 
sensations, thoughts and emotions. It is the site of memory, and it regulates the 
involuntary inner workings of the body such as the function of the heart and lungs. The 
brain cell  work together, communicating  by means of electric signal. Occasionally 
there is an abnormal electrical discharge from a group of cells, and the result is a 
seizure. The type of seizure will  depend upon the part of the  brain where the abnormal 
electrical discharge arises (82). Epilepsy is serious brain disorder. It is universal, with 
no age, sex, geographical, social class or racial boundaries(83). Some seizures are 
hardly noticed—perhaps a feeling of "pins and needles" in one thumb for a few seconds. 
During other seizures, the person may become unconscious, fall to the floor, and jerk 
violently for several minutes. 
2.11.1.1 Causes of epilepsy  
There is no single cause of epilepsy. Many factors can injure the nerve cells in 
the brain or the way the nerve cells communicate with each other. In approximately 
65% of all cases there is no known cause. The idiopathic epilepsies are those in which 
there is a clear genetic component, and they probably account for a third of all new 
cases of epilepsy. In significant proportion of cases however, no cause can be 
determined and these are known as the cryptogenic epilepsies. possible explanations for 
cryptogenic epilepsy include as yet unexplained metabolic or biochemical abnormalities 
and microscopic lesions in the brain resulting from brain malformation or trauma during 
birth or other injury. The term symptomatic epilepsy indicate that a probable cause has 
been identified .  
The following are some of the most frequently identified causes : 
 Brain injury: The onset of seizures after a brain injury often occurs after such a 
delay, even of many years. Researchers believe that this delay results from 
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reorganization of nerve connections in the injured areas. The brain makes an 
attempt to fix the injury by growing new connections, but the result is a circuit 
that is more electrically excitable and prone to produce seizures ( 84). 
 Head Trauma at birth 
 Stroke: During a stroke, brain cells die or are injured by blockage of blood flow 
to a part of the brain. About 10% of strokes lead to subsequent epilepsy. 
  Tumors 
 Infection: some condition known to have a risk of resulting in epilepsy is 
meningitis. 
 Vascular Malformations : abnormal blood vessels in the brain are common 
causes of epilepsy. Blood is brought to the brain by arteries. It flows into small 
capillaries, where oxygen is transferred to the brain cells, and then is carried out 
by veins. The brain cells near the malformation may be irritated by bleeding or 
lack of oxygen. The response to this irritation can be seizures ( 85). 
 Mutations in several genes have been linked to some types of epilepsy. Several 
genes that code for protein subunits of voltage-gated and ligand-gated ion 
channels have been associated with forms of generalized epilepsy and infantile 
seizure syndromes(86). One speculated mechanism for some forms of inherited 
epilepsy are mutations of the genes that code for sodium channel proteins; these 
defective sodium channels stay open for too long, thus making the neuron hyper-
excitable. Glutamate, an excitatory neurotransmitter, may, therefore, be released 
from these neurons in large amounts, which by binding with nearby 
glutamatergic neurons  triggers excessive calcium (Ca
2+
) release in these post-
synaptic cells. Such excessive calcium release can be neurotoxic to the affected 
cell. Another possible mechanism involves mutations leading to ineffective 
GABA (the brain's most common inhibitory neurotransmitter) action. 
 In some cases things that happen in the environment can trigger epileptic 
seizures (photosensitive seizure is defined as a seizure produced by flashing 
lights or certain visual patterns, for example television and video games. About 
3% of people with epilepsy will have photosensitivity .  
  The commonest cause in young infants are hypoxia , intercranial trauma during 




1. A person should only be diagnosed as having “epilepsy” if there are recurrent 
manifestations i.e. there should be at least two or more unprovoked similar 
episodes at least 24 hours apart. Hence, the first episode of a seizure is called a 
“single seizure” and not epilepsy. 
2. Epilepsy can also be divided into active and inactive epilepsy, with active 
epilepsy being defined as two or more epileptic seizures in the last five years 
that are unprovoked by any immediate identified cause. 
3. epilepsy can be diagnosed on the basis of reports of patients and eyewitnesses. 
Electroencephalography (EEG), which records electrical activity from the surface of 
the head can, in some cases, support the diagnosis(87). 
 
2. 11.1.3 Treatment of Epilepsy 
Antiepileptic drugs commonly used for treating epilepsy are carbamazepine, 
phenytoin, primidone, phenobarbital, and more recently, sodium valproate. All display a 
similar efficacy; major differences have to do with their adverse-effect profiles (88). 
Mechanism of action of antiepileptic drugs     
Three main mechanisms appear to be important in the action of antiepileptic drugs(89). 
 Enhancement of GABA action. 
 Inhibition of sodium channel function. 
 Inhibition of calcium channel function . Other mechanisms include inhibition  of  
glutamate release and block of glutamate receptors. 
2.11.1.3.1 Valproic acid 
Valproic acid (VPA, 2-propylpentanoic acid), a short branched chain fatty acid, 
it has been used worldwide for decades, in the form of sodium valproate, as an 
antiepileptic drug with therapeutic value for absence, partial, complex, myoclonic, 
tonic-clonic seizures (90), and photosensitive epilepsies(91). Valproate is believed to 
affect the function of the neurotransmitter GABA in the human brain, Its mechanism of 
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action includes enhanced neurotransmission of GABA (by inhibiting GABA 
transaminase, then GABA would increase in concentration). Valproic acid also blocks 
the voltage-gated sodium channels and T-type calcium channels. These mechanisms 
make valproic acid a broad spectrum anticonvulsant drug. Valproic acid is usually 
absorbed rapidly from the GIT. Peak serum concentrations are recorded at 1-4 hours. 
Valproic acid is greater than 80-95% protein bound. However, this percentage decreases 
during acute overdose, when protein-binding sites are saturated (92). Valproic acid is 
metabolized primarily in the liver by means of conjugation to form a glucuronide ester  
and by means of oxidation by mitochondria. Less than 5% is excreted unchanged in the 
urine. Many of the metabolites are biologically active and contribute to anticonvulsant 
action. They may also be responsible for ongoing toxicity (e.g. persistent coma) even as 
serum levels of valproic acid return to normal. The elimination half-life varies from 5-
20 hours. The half-life may be increased in neonates, in patients with liver disease, and 
in those ingesting an acute overdose. The half-life is 4-14 hours in children, 8-17 hours 
in adults, and up to 30 hours in those with an acute overdose. Valproic acid increases 
serum levels of carbamazepine, phenobarbital, and primidone mainly by inhibiting 
various cytochrome P450 (CYP450) isoenzymes involved in their metabolism(93). 
 serious complications of valproic acid, including hepatotoxicity(with an overall 
incidence of 1 in 20,000, but a frequency as high as 1 in 600 or 1 in 800 in high-risk 
groups such as infants below 2 years of age receiving anticonvulsant polytherapy) (92) 
and hyperammonemic encephalopathy, may occur. These complications may also arise 
following acute VPA overdose (94). VPA has significant side effects: weight gain, 
tremor, hair loss, GI upset, blood count decreases, hepatic or pancreatic injury, bone 
weakness over time (osteoporosis), birth defects in up to 10%.  Brand  names of 
valproic acid are  depakine,  Depakote,  Depakene, Depakote ER, Depacon, Valparin 







The usual dosage of valproic acid  is 1-15 mg/kilogram of body weight per day 
and may be increased to 30 mg/kilogram of body weight per day. It is usually taken two 
to three times a day. 
2.12 Prevalence of psychotic disorders among Palestinian population  
After the global financial crisis that caused the increase in poverty and 
unemployment, and caused an increase in the incidence of mental illness in general. 450 
million people in the world suffer from a   mental or behavioral disorder (95), More 
than 150 million suffer from depression at any point in time (96), 25 million suffer from 
schizophrenia (97), and more than 90 million suffer from an alcohol or drug use 
disorder, and nearly one million patients die annually by suicide (98). While in the Gaza 
Strip frequented more than 35 000 patients between the different mental illnesses. In 
general there are gradually increase of incidence rate of mental disorder. In 2009 there 
were 1,697 patients visits PHC centers with increase percentage 38.4% if compared 
with 2008, there's 13.1 % schizophrenic patients from new cases of mental disorders 
reported in 2009 (99).  
 
2.13 Prevalence of epilepsy disease among Palestinian population 
It is known that epilepsy is a chronic neurological disorder that affects people of 
all ages, its around 38 million people worldwide have epilepsy (95) , While in Gaza  







2.14 Previous studies 
      Lomas et al (1955)., had recorded a number of cases where they developed  jaundice  
after treatment by CPZ (100). 
      Willmore et al (1978)., tested hepatic function in 25 cases treated with valproic acid. 
Alteration of  hepatic function tests occurred in four of 25 patients treated with valproic 
acid. An average dose reduction in three patients of 10 mg per kilogram per day resulted 
in reversion of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic 
pyruvic transaminase (SGPT) to normal. The drug was discontinued in one patient. 
Careful monitoring of hepatic function is required of patients being treated with 
valproic acid (101). 
Green (1984)., reported  49 fatal cases of hepatotoxicity caused by sodium valproate, 
analysed in detail the childhood fatalities reported in the United Kingdom (102). All of 
the seven children in this series had some pre-existing problem in addition to epilepsy;  
three or four had degenerative disease, four or five had developmental delay, and two 
had hepatomegaly. Most had refractory myoclonic epilepsy. All were on combinations 
of anticonvulsant drugs at the time of presentation and all the severe reactions occurred 
within 10 weeks of starting treatment. 
Callaghan
 
et al (1994)., showed that GGT and ALP may not be sensitive indicators 
of hepatocellular damage in patients taking anticonvulsant drugs as raised levels may 
only reflect enzyme induction (103). So they examined Serum F protein, which  is 
found in high concentration in the liver and levels are not influenced by enzyme 
induction. They  measured serum F protein levels in patients taking carbamazepine 
(CBZ) and phenytoin (PHT) as monotherapy and in patients receiving multiple drugs, 
they compared the results with patients taking sodium valproate (VPA). Serum F 
protein levels were elevated in 6%, 22% and 13% of patients receiving CBZ, PHT and 
VPA, respectively. Raised GGT levels were reported for both the CBZ (26%) and PHT 
(78%) groups. Raised ALP levels were observed in 16%, 25% and 4% of the CBZ, PHT 
and VPA groups  respectively.   
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Cˇ epelaka  et al (1998)., evaluated  the effects of VPA or CBZ monotherapy and 
VPA + CBZ comedication on the number of hepatic enzyme activities in sera of 
epileptic children; ALT, AST and GGT activities in sera of children treated with VPA(n 
= 42), or CBZ (n =36) taken as a monotherapy, with VPA+ CBZ combined therapy (n 
=36). The effect of VPA alone is greater on the activity of AST than on other enzymes, 
while CBZ therapy changes primarily the activities of GGT. The mean catalytic activity 
of AST was significantly elevated in groups on VPA, CBZ and VPA + CBZ treatment 
as compared to the control values. Changes in the ALT activity followed different 
patterns. The maximal increase was observed in the CBZ group with a smaller increase 
in the group on VPA+ CBZ polytherapy, whereas only 15% of patients receiving VPA 
showed an increase of the enzyme and GGT elevated in 23% of patient receiving VPA  
(104). 
 
De-ming and Mei-rong (2000).,  evaluated  the influence of antipsychotic drug 
on liver function of schizophrenic patients. Eighty-six schizophrenic patients were 
randomly divided into two groups. One group received the treatment of typical 
antipsychotic drug (chlorpromazine), another received the treatment of atypical 
antipsychotic drug (risperidone). The indeces of liver function in all patients were 
compared respectively before the treatment, after 4 and 8 weeks of treatment. The 
Results of  Liver function in the patients of schizophrenia group became remarkably 
abnormal after four weeks of treatment. The influence of atypical antipsychotic drug on 
liver function was lower than typical antipsychotic drug. There was significant 
difference between them (105) . 
Altunbaşak et al (2001)., investigated the effects of valproic acid (VPA) on renal 
tubular function, they examined 15 ambulatory children with epilepsy who received 
VPA for at least 6 months. None of the patients had mental retardation. Fourteen age 
and sex-matched children were used as a control group. No statistically significant 
differences were found between patients and control subjects with respect to blood urea 
nitrogen (BUN), creatinine (Cr), uric acid, creatinine clearance (Ccr), tubular 
reabsorption of phosphorus (TRP), urinary Ca:creatinine ratio, urinary pH and mean 
urinary beta2-microglobulin concentrations (P>0.05) (106). 
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Garcia-Unzueta et al (2003)., analyzed  the effects of antipsychotics on liver function 
tests  in a population of outpatients suffering from schizophrenia, 54 schizophrenic 
patients . were Versus 54 sex- and age-  healthy controls. Concentrations of AST, ALT, 
GGT, alkaline phosphatase, albumin, and bilirubin were determined using a Technicon 
Dax (Technicon Instruments Corp., Tarrytown, NY). Data was analyzed with the 
statistical package SPSS for Windows 7.0. Transaminases concentrations were slightly 
elevated in study patients compared to healthy controls, but without statistical 
significance. Patients with depot neuroleptic treatment (fluphenazine, a phenotiazine) 
had higher GGT (P=0.005), and lower concentrations of both serum albumin and 
bilirubin (P=0.054 and 0.056, respectively) than patients on oral treatment. Typical/ 
atypical antipsychotic treatment and the dosage of neuroleptic treatment (converted to 
mg of chlorpromazine/day) did not correlate with liver function tests (107).  
Lackmann (2004)., recorded a case of a 4-year-old boy with long-term sodium 
valproate  therapy who suddenly developed clinically relevant thrombocytopenia and 
signs of hepatotoxicity. Reduction of the VPA dosage led to clinical and laboratory 
parameter improvement, while discontinuation of therapy was not necessary (108). 
 
TsingHua (2004)., studied the difference in the effect on indices of liver function in 
schizophrenic patients treated with risperidone, clozapine or chlorpromazine. The 
indices of liver function in schizophrenic patients had been measured and analyzed 
before and after 4 and 8 weeks using risperidone, clozapine or chlorpromazine in 30 
cases respectively. There was no significant difference in the liver function caused by 
risperidone (P > 0.05). ALT levels were significantly higher caused by clozapine firstly, 
and then AST there was a significant difference (P < 0.01). ALT  levels were higher in 
the liver function caused by chlorpromazine, but after 5 weeks it was lower to the 
normal ranges. While bilirubin in cases treated with chlorpromazine  showed a 
significant difference (P < 0.01) (109). 
 
Attilakos et al (2006)., Investigated  by a long-term, prospective method, whether  
treatment with VPA monotherapy may alter serum uric acid concentrations and liver 
function tests in 28 ambulatory epileptic children.  ALT, AST, GGT, lactate 
dehydrogenase (LDH), and creatinine (Cr) were also measured before and at 6, 12 and 
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24 month. No statistically significant changes in serum uric acid, creatinine, and GGT 
were detected  while serum ALT, AST concentrations were significantly increased 
(110) . 
Sonmez FM et al (2006)., assessed  the effect of phenobarbital, carbamazepine  
and valproate on serum lipid profiles and lipoprotein (a) in 64 children with epilepsy 
aged between 1 and 15 years. The children were separated as group 1 (18 children), 
treated with phenobarbital, 5 mg/kg/day; group 2( 22 children), treated with 
carbamazepine, 10 to 15 mg/kg/day; and group 3 ( 24 children), treated with sodium 
valproate, 20 mg/kg/day. Plasma lipoprotein (a), total cholesterol, triglycerides, low-
density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein A 
and apolipoprotein B levels, and liver enzymes alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, and GGT were determined before the initiation 
of the treatment and at 3, 6, and 12 months of the treatment period. The mean age of 
children in group 1 was significantly low compared with those in groups 2 and 3 (P < 
0.05). The mean pretreatment lipid levels among the groups were not significantly 
increased. The mean lipoprotein (a) levels were significantly increased in all groups at 
3, 6, and 12 months of the treatment period (P < 0.05). The increase in ALT, AST, ALP, 
total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein 
cholesterol at 3, 6, and 12 months was statistically significant in group 1 (P < 0.05). The 
higher levels in lipoprotein (a) (mean > 30 mg/dL) were observed only in 
carbamazepine-treated patients at 6 and 12 months. The percentage of children with 
lipoprotein (a) levels over 30 mg/dL was 44%, 63%, and 33% in the  phenobarbital-, 
carbamazepine-, and valproate-treated children, respectively (111).  
 
Demirciog˘lu  et al (2008)., aimed to determine the effects of carbamazepine, and 
valproic acid on the serum lipids and liver function test. Thirty-eight epileptic children 
(18 males, 20 females, mean age 8.6 ± 3.9 years) were evaluated for serum lipids and 
liver function test results at the onset, the second and sixth months of antiepileptic 
therapy. The results of the children receiving carbamazepine ( n = 31) and valproic acid 
(n = 7) were compared. In addition, the values obtained at different periods of treatment 
were compared within each group. The differences in the serum lipid levels and liver 
(ALP, SGOT,SGPT, Total, Direct bilirubin and GGT) function test results of the 
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children in the carbamazepine group and the valproic acid group were not statistically 
significant  throughout the study. However, the total cholesterol, low-density 
lipoprotein, total cholesterol/high- density lipoprotein, and  GGT  levels were 
significantly increased in the  carbamazepine group during treatment (P < 0.05) but not 
in the valproic acid group (112).  
Ghozzi  et al (2011)., evaluated  the relationship between plasma concentrations 
of VPA and the occurrence of side effects especially hepatotoxicity in patients receiving 
high doses of VPA. From 128 patients treated by high doses of VPA, only 73 were 
included in this study. The  work showed that adverse effects and clinical signs of liver 
toxicity may be present in VPA concentrations generally considered in the therapeutic 
range especially when used in high doses and or combined with antiepileptic drugs like 


























Materials and Methods 
3.1. Study  design                                
 The present study is a case control  study . 
 
3.2. Setting of the study 
This study was carried out at Mental health clinics in Gaza. 
       3.3. Target population  
The target population was psychiatric and epileptic  patients from Mental Health 
Clinics in Gaza. All patients were receiving antipsychotic drugs (CPZ with T.H.P ) or 
antiepileptic drug (VPA) for more than one year . 
3.4. Study Sample  
Study sample comprised 220 subjects including 110 psychiatric and epileptic  
patients (55 psychiatric male and 55 epileptic children ) from Mental Health Clinics in 
Gaza and 110 healthy people as  a control group .  
3.5. Ethical consideration  
The necessary approval to conduct the study from Helsinki committee in the 
Gaza strip was obtained (Annex 1) and coordination with the Ministry of Health was 
fulfilled (Annex 2). The participants were given  a full explanation about the purpose of 
the study and assurance about the confidentiality of the information obtained through 
the questionnaire and blood analysis . 
3.6. Data collection 
An interview used for filling in the questionnaire which was designed for 
matching the study need. Face to face interviews were conducted by researcher to 
collect data. The questionnaire included personal and medical information (the name, 
age, disease, drug, duration of treatment).  
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3.7. Blood sampling and processing 
Blood samples were collected by the researcher from all subjects, five ml blood 
were obtained from each subject into vacutainer plain tubes and were left short time to 
allow blood to clot, then serum samples were obtained by centrifugation at 3000 rpm for 
10 min. Serum samples were kept in the deep freeze (-20 °C) until assayed.  
3.8. Biochemical analysis  
Serum Gamma glutamyltransferase (GGT), aspartate aminotransferase (AST), 
alanineaminotransferase (ALT), Serum urea, creatinine, uric acid, alkaline phosphatase 
(ALP), serum total and direct bilirubin (TB, DB) were analyzed using autoanlyzer 
biosystem  A 15 (French)  
3.8.1. Determination of serum Urea  
Serum urea was determined using LABKIT. 
Method : Urease –GLDH. Kinetic. 
Principle 
Enzymatic determination was done according to the following reaction 
  
  
                                Urease      
Urea + H2O +2H
+
                          (NH4)
+
2 + CO2 
 
 
                                      GLDH   
NH
+
4 + α-Ketoglutarate + NADH                           H2O + NAD
+
 + L-Glutamate 
 
























Reagent : R1   
                     
    Buffer                TRIS pH 7.8 
                               α Ketoglutarate 






75000 U/L   
 
 R2  
     Enzymes                GLDH 
                                    NADH 
  
 
                60000 U/L 
                0.32 mmol/L    
 
UREA CAL               Urea aqueous primary standard 50 mg/dl  
 
 
Preparation and stability of working reagent  
Working reagent (WR) 
 
R1 buffer (4 vol.) + R 2 substrate (1vol.) were mixed together . 
 
 The (WR) was stable  for 1 month at 2-8°C. 
 
UREA CAL:  Ready to use . 
 




Wavelength                                             340 nm 
 Temperature                                           37 C/ 15-25°C 
 Cuvette                                                   1cm light path  
 
Reading against distilled water was performed . 
 
 
Sample Standard  Blank  
1.0 1.0 1.0 WR (ml) 
 - 10 -  Standard (μl) 
10 -    -  Sample (μl) 
 
1. Mixing and reading the absorbance after 30 seconds (A1) and 90 seconds 
(A2) was performed. 






Urea in the sample (mg/dl) =             (∆A)Sample      X  50 (Calibrator conc.) 
                                                         (∆A) Calibrator 
                                                                                                           
3.8.2. Determination of serum Creatinine 
     
 Serum creatinine  was determined according to Jaffe using LABKIT . 
 




The rate of  formation of a colored complex between Creatinine and alkaline 
picrate was  measured . 







(Picric Reagent ) 
 
 
   Picric Acid 
 
 
  17.5 mmol/L 
 
Reagent 2 









Creatinine aqueous primary calibrator 
 
 




Preparation and stability of working reagent  
Mixing 1volume of R1 with 1volume of R 2 was performed . 





Wavelength                                             492 nm (490-510) 
 Temperature                                           37C/ 15-25°C 
 Cuvette                                                   1cm light path  
 





Sample calibrator Blank  
1.0 1.0 1.0 WR(ml) 
-  100 - calibrator (μl) 
100 -  - Sample(μl) 
 
Mixing and reading the absorbance after 30 seconds (A1) and 90 seconds (A2) was 
performed. 
Calculation 
Creatinine in the sample (mg/dl) =    (∆A)Sample       X  2 (Calibrator conc.)  
                                                         (∆A) Calibrator 
                                                                                                                        
3.8.3. Determination of serum Uric acid 
Serum uric acid  was determined according to Globe Diagnostics S.R.I 
Method : Enzymatic colorimetric  
Principle 
The rate of  formation of purple quinoneimine whose intensity of colour is 
proportional to the concentration of uric acid  is measured . 
Reagents  composition  
 





Borate Buffer  pH 7.0 
Uricase 







> 50 U/L 
> 300 U/L 
0.25 mmol/L 
1 mmol/L 
> 100 U/L  
≤ 0.095 g/L 
Standard : Uric acid 6 mg /dl  




Preparation and stability of working reagent  




Wavelength                                             550 nm (540-560nm) 
 Temperature                                          20, 25or 37C°C 
 Optical path                                             1cm  
 Reaction                                                  End point 
 
Sample Standard Blank  
1 ml 1 ml 1 ml Reagent A  
- 25 μl - Standard 
25 μl - - Sample 
 
Mixing and reading the absorbance after 10 min at 37°C or for 15 min at 20-25 °C was 
performed. 
Calculation 
Uric acid  in the sample (mg/dl) =    (∆A) Sample         X  standard/Cal. Conc. 
                                                         ∆(A) Standard/ Cal   
 
3.8.4. Determination of serum Alanine aminotransferase (ALT) 
Serum ALT  was determined according to Globe Diagnostics S.R.I 
Method  
Optimized UV test according to Scandinavian Committee on Enzymes (SCE). 
Principle 
Enzymatic determination was done according to the following reaction 




                                         ALT           
L-Alanine + 2-Oxoglutarate                    L-Glutamate + Pyruvate 
                                         
                                           LDH 
Pyruvate + NADH +H                   L-Lactate + NAD  
















Preparation and stability of working reagent  
Mix 10 volumes of reagent A+ 1volume of reagent B (monoreagent) was done . 
WR was stable for : 4 weeks at 2-8 °C 
                        5 days at 15-25 °C  
Procedure  
Wavelength                                           340 nm, Hg 365 nm, Hg 334 nm 
 Temperature                                          37°C 
 Optical path                                           1cm 






             TRIS buffer 
             EDTA –Na2 
              L-Alanine 
              LDH 
             Sodium azid 
  
 
             28 mmol/L 
             5.86 mmol/L 
             568 mmol/L 
              ≥ 1700 U/L 
              2 g / L 
 
Reagent B 
               2-Oxoglutarate 
                NADH 
                Sodium azid 
 
 
               68 mmol/L 
               1.12 mmol/L 
                0.095 g/ L 
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   All reagents reached to working temperature before use 
 
Monoreagent   Procedure 
 1000 µl      Monoreagent 
  100 µl Sample                             
Mixing and reading absorbance after 1 min then 
again after 1, 2 and 3 min was done . 
                                            
Calculation  
From absorbance reading calculation ∆ A/min and multiply by the corresponding 
factor from the table  below was performed  
 
ALT  activity ( U/L) = ∆ A/min X factor (f) 
Monoreagent  procedure  
                              340 nm            f =1746 
365 nm          f = 1780 
                              365 nm            f  = 3235 
3.8.5. Determination of serum Aspartate aminotransferase (AST) 
Serum AST  was determined according to Globe Diagnostics S.R.I 
Method: Optimized UV test according to Scandinavian Committee on Enzymes (SCE). 
Principle 
Enzymatic determination was done according to the following reaction 
                                                       AST 
L-Aspartate + 2-Oxoglutarate                    L-Glutamate + Oxalacetate  
                                                 MDH 


















 MDH(Malate dehydrogenase) 
Sodium azid 
 
             28 mmol/L 
             5.68 mmol/L 
              284 mmol/L 
              ≥ 800 U/L 
              2 g / L  
R B 
               2-Oxoglutarate 
                NADH 
                Sodium azid 
 
              68 mmol/L 
              1.12 mmol/L 
               0.095 g/ L 
  
Preparation and stability of working reagent  
Mix 10 volumes  of reagent A+1volume of reagent B (monoreagent) was done . 
WR was stable for : 4 weeks at 2-8 °C 
                                 5 days at 15-25 °C  
Procedure  
 Wavelength                                           340nm, Hg 365, Hg334nm 
 Temperature                                          37°C 
 Optical path                                           1cm 
  Reaction                                                Kinetic   
All reagents reached to working temperature before use 
Monoreagent   Procedure 
 1000 µl     Monoreagent 
                100 µl Sample                             
Mixing and reading absorbance after 1 min then 




From absorbance reading calculation ∆ A/min and multiply by the corresponding 
factor from the table  below was performed  
 
AST  activity (U/L ) = ∆ A/min X factor (f) 
Monoreagent  procedure  
                              340 nm            f =1746 
                              334 nm            f = 1780 
                              365 nm           f  = 3235 
3.8.6. Determination of serum Alkaline phosphatase (ALP) 
Serum ALP was determined according to Cromatest 
Method : Kinetic  
Principle 
Enzymatic determination was done according to the following reaction 
 
                                             ALP, Mg 
4-Nitrophenylphosphate  + H2O                         4-Nitrophenol + Pi 
                                                        pH > 9                  






     
    ALP buffer . DEA buffer 
     Magnesium chloride biocides  
 
 
      1.25 mol/L pH 10.2 
      0.6 mmol/L  
 
Reagent 2 
      ALP substrate .4-NPP biocides 
 
        50 mmol/L  
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Preparation and stability of working reagent  
Working reagent (WR) 
R1 (4vol.) +R2 (1vol.) were mixed. 
   The (WR) was stable  for 5 days at 20-25°C or 15-30 days at 2-8°C 
Procedure  
Wavelength                                             405 nm  
 Temperature                                           25 /30/  37°C 
Cuvettes                                                   1cm pathlength    
Reading  against distilled water was performed .   
 
 1.0 mL     Working reagent  
    20 μL    Samples or control 
 
 
1-reagents were mixed  and incubated for 1 min and initial absorbance was performed, 
the absorbance readings were repeated  exactly after 1, 2 and 3 min was done . 
2-The difference between a absorbance's and calculation the mean of results to obtain 
the average change in absorbance per min (∆A/min) was obtained . 
Calculation  
U/L = ∆ A/min X 2764 
3.8.7. Determination of serum Gamma glutamyltransferase (GGT) 
Serum GGT was determined according to International Federation of Clinical 
Chemistry (IFCC) by Diasys Diagnostic Systems GmbH 
Method : Kinetic photometric test  
Principle 
                                                                          Gamma-GT   










Reagent  1 
                TRIS           pH 8.25 
                Glycylglycine 
 
                 135 mmol/L 
                 135 mmol/L 
 
  Reagent 2           




                 22 mmol/L 
 
 
Preparation and stability of working reagent  
Sample start  
R1 (4 vol. ) + R 2 (1vol. ) were mixed . 
WR: was stable 4 weeks at 2-8 °C or 5 days at 15-25 °C 
Procedure  
Wavelength                                             405 nm (400-420 nm) 
 Temperature                                            37°C 
Optical path                                             1cm   















Blank      
 
Sample   Start 
 
 
               100 μL 
 
 




-          
 
            100 μL 
 
Dist .Water                   
1000 μ L         1000 μ L Monoreagent 
  Mixing, incubation for approx.1min was performed, then reading 
again after 1, 2, and 3 min was done . 
Calculation  
U/L = ∆ A/min X 1309 
3.8.8. Determination of serum Bilirubin (Total and Direct ) 
Serum bilirubin  was determined according to diazotized sulfanilic by Biosystem  S.A 
Method: Colorimetric  
Principle 
Coloured complex formed as a result of reaction between direct bilirubin in the sample 
and  diazotized sulfanilic acid, both direct and indirect bilirubin coupled with diazo  in 







Reagents  composition 















sodium nitrite 11.6 mmol/L 





                              
 Sulfanilic acid                  
 Hydrochloric  acid 
     
 35 mmol/L 
 0.24 mol/L 
 sodium nitrite  3.5 mmol/L 
Bilirubin Standard:  reconstituted with 5 ml distilled water . 
It was stable for 4 hours at 15-30 °C or for 2 month at  -18°C when frozen in aliquots. 
Preparation and stability of working reagent 
Working reagent: transferred the contents of one reagent BT vial into a reagent 
AT bottle for total bilirubin, or one reagent BD vial into a reagent AD bottle for direct 
bilirubin  was done. Other  volumes prepared in proportion: 1ml reagent BT + 4 ml 
reagent AT or 1 ml reagent BD +4 ml reagent AD. It was stable for 20 days at 2-8 °C . 
Procedure  
Wavelength                                             540 nm (520 -560 nm) 
Temperature                                            37°C 
 Cuvette                                                   1cm light path  
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Working reagent  
 
1) Mixing the stand tubes for 2 minutes at room temperature was done. 
2)   Reading the absorbance (A) of the sample blanks at 540 nm against 
       distilled  water was performed. 
3)  Reading the absorbance (A) of the samples and standard at 540 nm 
against the reagent blank was done .   


























Working reagent  
 
1. Mixing the  stand tubes for exactly 5 minutes at 37°C was done   
2. Reading the absorbance (A) of the sample blanks at 540 nm against distilled  
water was performed. 
3. Reading the absorbance (A) of the samples and of the standard at 540 nm 





Sample ( mg/dl )      =     A sample  - A sample blank     X  C standard       
                                          A standard                                                                                                                                                                               
In calculation of Direct Bilirubin, the absorbance of the standard in Total Bilirubin was 
used. 
3.9. Statistical analysis  
Data  were computer analyzed using SPSS (Statistical Package for Social 
Science ), then the variables of the study were conducted to multiple statistical tests 
according to types of variables such as (t – test , chi –square test (X²) ). Result analyzed 
were expressed as mean ± SD. result was considered statistically significant if the p-

























4.1. General characteristics of study  population 
The present study is a case control  study which  included 220 subjects from 
both genders; 110 healthy controls and 110 patients receiving drugs for more than one 
year, 55 of patients  suffered from epilepsy and receiving valproic acid  as antiepileptic 
drug while the remaining of cases were psychiatric patients and receiving 
chlorpromazine with T.H.P as antipsychotic drug.  patients  comprised 55 males and 55 
children's. 
4.2. Distribution of patients according to disease  
  As shown in Table 4.1,  the percentage of patients suffering from  schizophrenia 
was 44.5%, while those suffering from  epilepsy was 47.3% and those having mental  
retardation was 8.2% , of the study cases.  
Table 4.1 : Distribution of cases with respect to diseases  
Disease  Number (n=110) Percent (%) 
Schizophrenia  49 44.5 
Epilepsy  52 47.3 
Mental Retardation  9 8.2 
4.3.Distribution of patients according to residency  
Table 4.2 reveals that there was 33.6% of cases from North Governorate, while 30.9% 
were from Gaza,  27.3% from Middle Zone and 8.2% from South Governorate .  
Table 4.2: Distribution of patients according to residency 
Governorate  Number (n=110) Percent (%) 
North  37 33.6 
Gaza  34 30.9 
Middle 30 27.3 
South  9 8.2 
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4.4 Age of subjects 
Table 4.3 shows there was no significant difference between cases and control 
groups in relation to their age. The mean age of children control  is 7.9 ± 3.52 while the 
mean age in male control is 36.8±13.97. The mean age of epileptic children is 8.7±3.70 
while the mean age in male  psychiatric patients is 40.1 ± 10.90.  This applies to 
patients who were receiving VPA ( t= -1.138, p = 0.258), as well as those who were 
receiving CPZ & T.H.P (t = -1.355, P = 0.178) . 






Mean ± SD 
 
Case (n=55) 



























VPA: Valproic acid,  CPZ: chlorpromazine hydrochloride,  T.H.P: Trihexyphenidyl 
hydrochloride. 
4.5 Distribution of subjects based on receiving regular or irregular 
treatment  
Table 4.4 shows  that 37 patients received VPA regularly  and 18 patients 
irregularly , 50 patients  received  CPZ with T.H.P regularly  and 5 patients received  
drugs irregularly.  
Table 4.4 Distribution of cases  based on regularity of drug  treatment 
Type of treatment Regular (n=87) Irregular (n=23)  X² P-value 
VPA 37 18  
9.290 
 
0.002 CPZ& T.H.P 50 5 




4. 6. Assessment of liver function in epileptic patients receiving Valproic. acid 
 Table 4.5 shows the results of  liver function tests among epileptic patients 
receiving VPA as antiepileptic drug, there was no significant difference (t = -1.320, p 
=.190) between  cases (26.60±12.03 u/l) and control (24.07±7.54 u/l) in  ALT test. 
There was high statistically  significant difference (t = - 4.306, p = 0.000) between cases 
(34.38±14.06 u/l) and control (25.13±7.52 u/l) in AST test. While there was no 
significant difference  observed in ALP test (t = 1.470,  p = 0.145) when compared  
between cases (472.1± 168.3 u/l) and control (519.1±167.5 u/l), the same result was 
found  in GGT test (t = -1.678, p=0.096)  when compared between cases(17.4±6.2 u/l) 
and control( 15.9±3.3 u/l), also there was no significant difference(t = 0.585, p = 0.560) 
between  Total bilirubin in cases (0.79±0.28 mg/dl) and control (0.82±0.16 mg/dl). In 
Direct bilirubin  there was no significant difference  ( t = -1.127, p = 0.262) between 
cases (0.24 ± 0.15 mg/dl) and controls (0.21±0.09 mg/dl).  
Table 4. 5 : Liver function  tests  of study population  receiving  Valproic Acid. 
Parameter Control (n=55) 
Mean ± SD 
Case (n=55) 
Mean ± SD 














-4.306  0.000 
ALP (u/l)         
 




























ALT: alanine aminotransferase,  AST: aspartate  aminotransferase, ALP: alkaline 
phosphatase, GGT: Gamma glutamyl transferase . 
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4.7. Assessment of kidney  function in epileptic patients receiving 
Valproic. acid   
 Table 4.6 illustrates that there was no significant difference ( t = - 0.179,  p = 
0.858) between epileptic patients (25.69±9.2 mg/dl) who were receiving VPA and 
control (25.42±6.6 mg/dl) in Urea test. likewise there was no significant difference (t=  -
0.871, p =  - 0.386) between   cases (0.66±0.15 mg/dl) and control (0.64±0.14 mg/dl) in 
Creatinine test. As  well, there was no significant difference ( t= - 0.579, p = 0.564) 
between cases (4.24±1.21 mg/dl) and control (4.11±1.03 mg/dl) in  Uric acid test .   
Table 4. 6 : Kidney Function Tests of study population  receiving  Valproic acid.   
Parameter  Control (n=55)        
    Mean ± SD 
       Case (n=55) 
         Mean ± SD 
T P-value 


















Uric acid (mg/dl)   4.11±1.03 4.24±1.21 -0.579 0.564 
4.8. Assessment of liver function in psychiatric patients who were 
receiving chlorpromazine with Trihexyphenidyl hydrochloride. 
 Table 4.7 administrate  the liver test among psychiatric patients suffered from 
schizophrenia who were  receiving CPZ with T.H.P  drugs, there was no significant 
difference (t = -1.799, p = 0.075) between  cases (28.06 ± 12.8 u/l) and control 
(24.31±8.6 u/l) in  ALT test. There was statistically  significant difference  (t = - 2.965, 
p = 0.004) between cases (29.73±6.9 u/l) and control ( 25.31±8.7 u/l) in AST test. There 
was significant difference  in ALP test (t = -2.320,  p = 0.022) when compared between 
cases (209.4±87.2 u/l) and control (178.5±46.3 u/l). There was significant difference in 
GGT test (t= - 2.838, p=0.005 ) when compared between cases ( 30.9±30.2 u/l) and 
control(19.2±5.1 u/l). There was no significant difference ( t = - 1.477, p=0.143) in  
Total bilirubin between  cases (0.94±0.38 mg/dl) and control (0.85±0.17 mg/dl). In 
Direct bilirubin there was significant difference  (t = -3.485, p = 0.001) between cases 
(0.35±0.32 mg/dl) and controls (0.19±0.05 mg/dl).                                                                                             
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Table 4. 7 : Liver function  tests  of study population  receiving  chlorpromazine 
with Trihexyphenidyl hydrochloride 
Parameter Control (n=55) 
Mean ± SD 
Case (n=55) 
















ALP (u/l)         
 




























ALT: alanine aminotransferase,  AST: aspartate  aminotransferase, ALP: alkaline 
phosphatase, GGT: Gamma glutamyl transferase . 
4.9. Assessment of kidney function in psychiatric patients receiving 
chlorpromazine with Trihexyphenidyl hydrochloride 
Table 4.8 administrates  the kidney test among psychiatric patients suffered from 
schizophrenia who were  receiving  CPZ with T.H.P drugs. There was no significant 
difference (t = - 0.891, p = 0.375) between  cases (28.71±10.22 mg/dl) and control 
(27.24±6.8 mg/dl) in Urea  test. There was statistically  significant difference  ( t = - 
6.681,  p = 0.000) between cases (1.03±.18 mg/dl) and control(0.81±0.17 mg/dl) in 
Creatinine test. There was significant difference  in Uric acid  test (t = -2.208,  p = 





Table 4.8 : Kidney function tests of study population  receiving chlorpromazine 
with Trihexyphenidyl hydrochloride. 
Parameter  Control (n=55)   
Mean ± SD 
Case (n = 55) 
Mean ± SD 
T  P-value 

















-6.681  0.000 
Uric acid (mg/dl)  
 
 4.53±0.95 6.25±5.70 -2.208  0.029 
 
4.10. Assessment of liver function in epileptic patients according to 
regular or irregular treatment  
 Table 4.9 Illustrates that there was no significant difference (t = 1.418, p = 
0.162) between irregular ( 23.3±7.2 u/l) and regular patients ( 28.2 ± 13.6 u/l) in ALT 
test, while there was significant difference ( t= 2.673, p=0.010 ) in AST in irregular 
(27.5±10.0 u/l) and regular (37.7±14.6 u/l) patients. There was no significant difference   
( t=1.138  p = 0.260) of irregular (435.2±165.7 u/l) versus regular (490.0±168.8 u/l) in 
ALP. likewise there was  no significant difference in GGT ( t = 0.549, p = 0.585), total 
bilirubin (t = 0.511, p = 0.612), and direct bilirubin (t = 0.786, p= 0.435) between 
irregular case (16.8±6.3 u/l , 0.76±0.35 mg/dl, 0.23±0.11 mg/dl) and regular case 







Table 4.9: Liver function tests of patients with respect to regular or 
irregular treatment of Valproic Acid. 
 Parameter Regular  (n=37) 
Mean ± SD 
Irregular (n=18) 
Mean ± SD  














2.673  0.010 
ALP (u/l)         
 




























ALT: alanine aminotransferase,  AST: aspartate  aminotransferase, ALP: alkaline 
phosphatase, GGT: Gamma glutamyl transferase . 
4.11. Assessment of kidney function in epileptic patients according to 
regular or irregular treatment 
 Table 4.10 Illustrates that there was no significant difference (t = - 0.514, p = 
0.610) between irregular  (26.6 ± 10.5 mg/dl)  and regular patients (25.24 ± 8.6 mg/dl) 
in Urea test, also there was no significant difference (t = 0.053, p = 0.958) in Creatinine 
between irregular (0.66±0.14 mg/dl) and regular (0.66 ± 0.15 mg/dl) patients. Likewise 
there was no significant difference in Uric acid (t = - 0.517, p = 0.607) between 




Table 4.10: Kidney function tests of patients classified according  regular or 
irregular treatment of Valproic Acid. 
Parameter  Regular (n=37) 
Mean ± SD 
Irregular (n=18) 
 Mean ± SD 
T P-
value 


















Uric acid (mg/dl)  
 
 4.17±1.23 4.36±1.19 -0.517 0.607 
 
4.12. Assessment of liver function in psychiatric  patients according to 
regular or irregular treatment 
 Table 4.11  reveals  that there was no significant difference (t =1.263, p = 0.212) 
between irregular (21.2±11.4 u/l)  and regular patients (28.7 ±12.8 u/l) in ALT test, also 
there was no significant difference (t = 0.913, p = 0.365) in AST  in irregular (29.5 ± 6.8 
u/l) and regular (32.4 ± 7.5 u/l) patients. likewise there was no significant difference in 
ALP (t = 0.849, p = 0.400 ), GGT (t = 0.129, p= 0.898), Total bilirubin ( t = 0.088, p = 
0.930) and Direct bilirubin (t = 0.843, p = 0.843) among irregular case (206.2 ± 85 u/l, 
30.8 ± 31.6 u/l, 0.92 ± 0.51 mg/dl, 0.33 ± 0.30 mg/dl) and regular ones (241.0 ± 112.4 









Table 4.11 : Liver function tests of patients classified with regular or irregular 
treatment of chlorpromazine with Trihexyphenidyl hydrochloride                    
Parameter Regular (n=50) 
Mean ± SD 
Irregular (n=5)  
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ALT: alanine aminotransferase,  AST: aspartate  aminotransferase, ALP: alkaline 
phosphatase, GGT: Gamma glutamyl transferase . 
 
4.13. Assessment of Kidney function in psychiatric  patients according 
to regular or irregular treatment 
 Table 4.12  reveals  that there was no significant difference (t = - 0.112, p = 
0.912) between irregular (29.2 ± 7.3 mg/dl)  and regular patients ( 28.7 ± 10.5 mg/dl) in 
Urea test, also there was no significant difference ( t = - 0.387, p = 0.700) in Creatinine    
in irregular (1.06 ± 0.11 mg/dl) and regular (1.03 ± 0.18 mg/dl) patients. likewise there 
was no significant difference in Uric acid  (t = -1.081, p = 0.341), among irregular cases  




Table 4. 12 : Kidney Function tests of patients on regular or irregular treatment of 
chlorpromazine with Trihexyphenidyl hydrochloride                    
Parameter  Regular  (n=50) 
Mean ± SD 
Irregular (n=5) 
Mean ± SD 
T P-
value 


















Uric acid (mg/dl)  
 



















5.1 . Assessment of liver function in epileptic patients receiving 
Valproic acid 
In the present study we examined the liver function test in epileptic children 
receiving VPA for more  than one year. The results showed  that ALT, GGT, ALP, 
Total and Direct bilirubin were not statistically significant when these results were 
compared with those of control group. On the other hand,  AST activity was statistically 
significant among the study population. These findings are in agreement with other 
researchers (104) those  assessed liver function in 42 epileptic children who were 
treated with VPA, found only 15% of patients receiving VPA showed 6.3 cases of 42 
epileptic children had elevated level of ALT enzyme while  GGT elevated in 23% of 
patient receiving VPA which means about 9.6 cases had elevated level of GGT, In our 
study it was 14.5% cases of epileptic children who had elevated level of ALT enzyme, 
whereas in GGT elevated in 16.3% cases of epileptic children. Other researchers 
obtained the same results with  the exception of AST where they found no difference 
between patients and control groups (111). This controversy between the present 
findings and theirs may be due to different  sample size  and  the fact that their target 
group might have administered the drug for longer periods. The present findings   
showed a significant difference in relation to AST, which is due to  the fact that AST is 
distributed in many other organs beside liver. Muscle cells contain appreciable amounts 
of this enzyme. It is well known that antiepileptic drugs affect muscles causing their 
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relaxation, which may be the cause of elevated activity of AST in these  patients. 
Among our  patients, 14.5%  of them had elevated levels in ALT and 16.3%  with GGT. 
This finding  could be explained on the basis that these administered high doses over a 
long period of time. Other studies (101, 108) correlated high doses with abnormal liver 
functions. We expect that  these children  patients did not receive special care and 
attention from their families in relation to drug administration.  
 
Other studies (110 ) reported the same results with a slight difference in relation 
to ALT and AST where they significantly increased after two years of treatment with 
VPA. These difference may be due to the fact that their target group might have 
administered the drug for longer periods. Elevated level in these enzymes may be due to 
genetic, environmental factors or preexisting of another disease affected the liver.  Our 
findings  showed no significant difference in relation to ALP, TB, DB, and GGT   
which coincides with other studies (112). 
Other  study (101) tested hepatic function in 25 cases treated with VPA. Four 
patients had abnormal liver function test results. When the dose of VPA was reduced to 
10 mg/kg/day, liver function became normal. This finding emphasized role of dose 
adjustment. In  the present  study most  of patients probably receive the correct dose of 
VPA. Also other study  (113) evaluated  the relationship between plasma concentrations 
of VPA and the occurrence of side effects especially hepatotoxicity in patients receiving 
high doses of VPA. The  study  showed that adverse effects and clinical signs of liver 
toxicity may be present in VPA concentrations generally considered in the therapeutic 
range especially when used in combination with antiepileptic drugs like phenobarbital 
or carbamazepine  and benzodiazepines. 
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  A documented study in UK (102) reported 49 cases of hepatotoxicity caused by 
VPA  which ends in death. However, most of those children had other pre-existing 
problems in addition to epilepsy. Other studies looked for more sensitive indicators than 
GGT and ALP for liver damage such as serum protein F (103). They found that serum 
protein F levels were elevated in 13% of patients receiving VPA, GGT levels were not 
raised, ALP elevated levels were observed in 4% of VPA groups. These  performing 
more sensitive indicators to detect the signs of liver damage progression as early as 
possible is recommended moreover. every community has its own traditions and habits 
which affect their attitudes towards administering drugs regularly or intermittently or 
even stop drug administration without physician advice.  In addition we cannot ignore 
the deteriorating economic conditions of our society which acts as a barrier of 
purchasing the drugs regularly. 
 
5.2 Assessment of kidney function in epileptic  patients receiving VPA. 
 The present  study showed no significant differences between patients and 
control group in relation to kidney function. All tests (urea, creatinine,  and uric acid) 
proved to be normal in both groups. This findings  is in agreement  of Altunbasak et al 
(106) who found no statistically significant differences between patients and control 
subjects with respect to blood urea nitrogen, creatinine, uric acid , and creatinine 
clearance. Other study  (110) evaluated the effect of VPA on renal enzyme activities in 
sera of epileptic children. They found that creatinine and uric acid were not statistically 
significant, similar to present finding . It seems that the kidney is not affected by the 
metabolites of VPA  and these molecules do not cause nephrotoxicity. The dose of VPA 
is considered to be in the therapeutic range. It means  VPA is  safe for long term  
treatment and not toxic to liver or kidney when used in suitable dose.                               
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5.3. Assessment of liver function in psychiatric patients who were 
receiving chlorpromazine and trihexyphenidyl hydrochloride.    
 Our study  showed  that patients who were receiving CPZ with T.H.P had 
abnormal liver function tests namely AST, ALP, GGT, and DB. These findings  are in 
agreement with those obtained by Garcia-Unzueta et al (107). They assessed liver 
function in 54 schizophrenic  patients and recorded elevated levels of ALP, GGT, and 
bilirubin. However  De-ming and Mei-rong (105) evaluated  the influence of 
antipsychotic drug on liver function of eighty-six schizophrenic patients who were 
randomly divided into two groups. One group received the treatment of typical 
antipsychotic drug (CPZ), another received the treatment of atypical antipsychotic drug 
(risperidone). The indeces of liver function in all patients were compared respectively 
before the treatment,  and after 4 and 8 weeks of treatment.  Despite of short duration of 
treatment, the results of  liver function in the patients of schizophrenia group became 
remarkably abnormal after four weeks of treatment. TsingHua (109) studied the 
difference in liver function in schizophrenic patients  treated with CPZ.  ALT levels 
were elevated after 8 weeks of treatment but after 5weeks it returned to its normal level. 
It is noted that the AST enzyme was   significantly  high among the cases.  
These results may be due to  the decomposition of red blood cells, especially that direct 
bilirubin was elevated  to significant level. This indicated the presence of post-liver 
problems such as hepatocellular  damage, intrahepatic and extrahepatic biliary tract 
obstruction which might lead to appearance of  jaundice  among the patients (100) . 
The variability in the findings of the above mentioned researchers might be due to many 
factors like socio-economic and, cultural ones. The commitment of patients to the 
prescribed dose and the high level of health care may contribute to understanding of this 
variability. However, the present  finding was  in agreement with the majority of other 
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studies . For this it is  recommended  to conduct regular assessment of liver function for 
patients receiving CPZ. with emphasis on detection of early markers like protein F.        
                                                                                                    
5. 4 Assessment of kidney function in psychiatric patients receiving 
chlorpromazine and trihexyphenidyl hydrochloride.     
 Our findings  showed that kidney function is affected by the administration of 
CPZ & T.H.P. This is indicated by significant differences between cases & control 
groups in relation to creatinine & uric acid, on the contrary urea levels were not 
significant. Kidney impairment may be due to the fact that some CPZ is excreted 
unchanged in urine and due to high lipophilic characters of its metabolites,  it may be 
detected in the urine up to 18 months which may cause long term toxicity of the kidney 














Conclusion and Recommendation  
6.1 Conclusion 
 
1.  Among the cases  the percentage of patients who were suffering from  
schizophrenia was 44.5%, while those suffering from  epilepsy represented by 
47.3% , 8.2%  had mental retardation. 
2. In this study  67.3%  patients received VPA regularly  and 32.7% patients 
irregularly,  90.9%  patients were  receiving CPZ with T.H.P regularly  and 
9.1% patients received  drugs irregularly .  
3. In  epileptic children  receiving VPA as antiepileptic drugs, there was high 
statistically  significant difference   between cases and control in AST test.  
4. There was no significant difference between epileptic patients who were  
receiving VPA and control groups in  relation to blood  urea  test. likewise there 
was no significant difference between   cases and control in creatinine and  uric 
acid tests .  
5.  Among psychiatric patients suffered from schizophrenia there was high 
statistically  significant difference between cases and control groups in AST,  
ALP, GGT, and DB  tests (P< 0.05). 
6.  The kidney test among psychiatric patients suffered from schizophrenia who 
were receiving CPZ with T.H.P drugs, there was high statistically  significant 
difference  between cases  and control groups in creatinine test and uric acid (p < 







6.2 Recommendations   
1. The patients should be regularly tested for kidney and liver function 
every month . 
2. Monitoring  drug levels in the blood should be carried out regularly. 
3. Follow-up patients in their homes is recommended.  
4. Introduction of more sensitive tests for liver damage like protein F. 
5. More research  as are  needed to be conducted such as the effect of 
anti-epileptic & antipsychotic drugs on endocrine  glands . 
6. Lactate dehydrogenase (LDH) and lipids especially lipoprotein (a) 
levels  and weight should be monitored in patients receiving VPA . 
7. Laboratory tests which  detect early damage of the kidney e.g. renal 
enzymes and microalbumin are recommended. 
8. New a typical antipsychotic drugs should be used to treat Mental 
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